+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Forecast 2024-2030- Product Image
Global Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Forecast 2024-2030- Product Image
Sale

Global Antibody Drug Conjugate Market by Mechanism of Action (CD30 Antibodies, ErbB2 Antibodies), Drugs (Adcetris, Blenrep, Enhertu), Technology, Indication, End User - Forecast 2024-2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5896370
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibody Drug Conjugate Market size was estimated at USD 5.60 billion in 2023, USD 6.48 billion in 2024, and is expected to grow at a CAGR of 16.12% to reach USD 15.96 billion by 2030.

The antibody drug conjugate (ADC) includes developing, manufacturing, and commercializing therapeutic molecules that combine monoclonal antibodies with cytotoxic agents. These hybrid compounds selectively target and eliminate cancer cells while minimizing toxicity to healthy tissue. ADCs are widely used in oncology due to their enhanced efficacy and reduced side effects compared to traditional chemotherapy. The continuous rise in cancer prevalence globally fuels the need for innovative therapies such as ADCs.

However, the complexity of the manufacturing process for ADCs can be challenging, as they require multiple steps and stringent quality control measures to ensure product homogeneity and stability. Moreover, research is being conducted on applying ADC technologies to other diseases beyond oncology, including autoimmune disorders and infectious diseases, which is expected to encourage the utilization of ADCs by the end-use sectors worldwide.

Regional Insights

The antibody drug conjugates (ADCs) market is evolving in the Americas due to advancements in oncology and the need for targeted therapies. A robust research infrastructure and a favorable environment for innovation encourage growth of ADCs in the Americas. In the European Union (EU), centralized marketing authorization for ADCs is provided by the European Medicines Agency (EMA). The EU has observed several strategic collaborations to develop novel ADC therapy in recent years.

The Middle East and Africa region presents untapped potential due to increasing healthcare expenditure and growing awareness of targeted therapies. Increasing R&D expenditure coupled with the prevalence of cancer are raising the need for ADCs in the APAC region. Additionally, introducing and utilizing advanced technologies for manufacturing ADCs is anticipated to increase their adoption by the end-use sectors across the globe.

Market Trends by Segment

  • Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
  • Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
  • Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
  • Indication: Rapid usage of ADCs for efficient treatment of breast cancer
  • End User: Emerging use of ADCs by academic research institutes for novel developments

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Lonza to enhance commercial antibody-drug conjugate supply capacity

Lonza has constructed a commercial-scale cGMP filling line at its site in Stein, Switzerland. This initiative aims to enhance Lonza's ability to cater to the bioconjugates and ADC markets. With the introduction of the new filling line, Lonza is capable of manufacturing highly potent antibody drug conjugates (ADCs) and facilitating lyophilization for commercial supply. The construction of the filling line is part of an extended customer agreement, which will support the clinical and commercial supplies of bioconjugates.

ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

ENHERTU is an antibody drug conjugate (ADC) developed by Daiichi Sankyo and AstraZeneca. It is designed to target HER2 and has been recommended for approval in the European Union for adult patients treatment with advanced non-small cell lung cancer. The development and joint commercialization efforts of Daiichi Sankyo and AstraZeneca have provided the way for patients treated with advanced non-small cell lung cancer with an activating HER2 mutation.

Pyxis Oncology Successfully Completes Acquisition of Apexigen

Pyxis Oncology, a clinical-stage biopharmaceutical company, acquired Apexigen, Inc., a developer of antibody drug conjugates with a focus on innovative oncology therapeutics. This strategic move has positioned the combined company at the forefront of antibody drug conjugate (ADC) innovation. This merger enables Pyxis Oncology to leverage Apexigen's expertise and resources in advancing next-generation therapeutics for the treatment of difficult-to-treat cancers.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugate Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ADC Therapeutics SA, Ambrx Biopharma Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, BioNTech SE, Bristol-Myers Squibb Company, Byondis B.V., Celldex Therapeutics Inc., Creative Biolabs, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Heidelberg Pharma AG, ImmunoGen, Inc., Innate Pharma SA, Innovent Biologics, Inc., Lonza Group Ltd., MacroGenics, Inc., MediLink Therapeutics, Merck KGaA, Mersana Therapeutics, Inc., Novartis AG, Oxford Biotherapeutics Limited, Pfizer, Inc., Pheon Therapeutics Ltd., Piramal Pharma Limited, Recipharm AB, Sanofi S.A., Sorrento Therapeutics, Inc., Tagworks Pharmaceuticals BV, Takeda Pharmaceutical Company Limited, Tubulis GmbH, and Zymeworks Inc.

This research report offers invaluable insights into various crucial aspects of the Antibody Drug Conjugate Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of cancer worldwide
5.1.1.2. Growth in clinical trial activities and robust product pipeline
5.1.1.3. Government support and initiatives encouraging research on cancer
5.1.2. Restraints
5.1.2.1. High manufacturing cost of ADC and incidences of product recalls
5.1.3. Opportunities
5.1.3.1. Increasing investment in biopharma R&D and introduction of novel ADCs
5.1.3.2. Adoption of advanced technologies for developing ADC
5.1.4. Challenges
5.1.4.1. Complexity in manufacturing of ADCs
5.2. Market Segmentation Analysis
5.2.1. Mechanism of Action: Increasing preference for ErbB2 antibodies (HER2) for effective treatment of breast and gastric cancer
5.2.2. Drugs: Penetration of Enhertu as a promising drug for targeted therapies in the oncology field
5.2.3. Technology: Preference for linkerless technology for simplifying the manufacturing process and improving the stability of ADCs
5.2.4. Indication: Rapid usage of ADCs for efficient treatment of breast cancer
5.2.5. End User: Emerging use of ADCs by academic research institutes for novel developments
5.3. Market Trend Analysis
5.3.1. Significant emphasis on securing approval for novel ADC drugs in the Americas
5.3.2. Cancer burden coupled with improving healthcare infrastructure in the APAC region
5.3.3. Supportive government initiatives for improved cancer research and treatment in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis
6. Antibody Drug Conjugate Market, by Mechanism of Action
6.1. Introduction
6.2. CD30 Antibodies
6.3. ErbB2 Antibodies
7. Antibody Drug Conjugate Market, by Drugs
7.1. Introduction
7.2. Adcetris
7.3. Blenrep
7.4. Enhertu
7.5. Kadcyla
7.6. Padcev
7.7. Trodelvy
8. Antibody Drug Conjugate Market, by Technology
8.1. Introduction
8.2. Cleavable Linker
8.3. Linkerless
8.4. Non-Cleavable Linker
9. Antibody Drug Conjugate Market, by Indication
9.1. Introduction
9.2. Blood Cancer
9.3. Breast Cancer
9.4. Lymphoma
9.5. Multiple Myeloma
9.6. Urothelial Cancer & Bladder Cancer
10. Antibody Drug Conjugate Market, by End User
10.1. Introduction
10.2. Academic Research Institutes
10.3. Biopharmaceutical & Biotechnology Companies
10.4. Hospitals
10.5. Specialized Cancer Centers
11. Americas Antibody Drug Conjugate Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Antibody Drug Conjugate Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Antibody Drug Conjugate Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. Lonza to enhance commercial antibody-drug conjugate supply capacity
14.3.2. ENHERTU Recommended for Approval in the EU by CHMP for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer
14.3.3. Pyxis Oncology Successfully Completes Acquisition of Apexigen
14.3.4. BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
14.3.5. Novartis-Backed Tagworks Raises USD 65 Million Series A to Further ADC, Click-to-Release Tech
14.3.6. Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
14.3.7. Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
14.3.8. BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
14.3.9. Pfizer Invests USD 43 Billion to Battle Cancer
14.3.10. AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
14.3.11. U.S. FDA Approves Trodelvy in Pre-treated HR+/HER2- Metastatic Breast Cancer
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
List of Figures
FIGURE 1. ANTIBODY DRUG CONJUGATE MARKET RESEARCH PROCESS
FIGURE 2. ANTIBODY DRUG CONJUGATE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
FIGURE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. ANTIBODY DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. ANTIBODY DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ANTIBODY DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CD30 ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ERBB2 ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ADCETRIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLENREP, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLENREP, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENHERTU, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ENHERTU, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY KADCYLA, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PADCEV, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY PADCEV, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRODELVY, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TRODELVY, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY CLEAVABLE LINKER, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LINKERLESS, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY NON-CLEAVABLE LINKER, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BLOOD CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BREAST CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY LYMPHOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY UROTHELIAL CANCER & BLADDER CANCER, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 61. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 62. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 63. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 64. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 65. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 66. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 67. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 68. AMERICAS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 71. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 72. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 73. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 74. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 75. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 76. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 77. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 78. ARGENTINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 79. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 80. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 81. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 82. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 83. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 84. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 85. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 86. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 87. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 88. BRAZIL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 89. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 90. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 91. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 92. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 93. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 94. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 95. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 96. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 97. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 98. CANADA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 99. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 100. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 101. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 102. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 103. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 104. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 105. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 106. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 107. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 108. MEXICO ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 110. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 111. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 112. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 113. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 114. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 115. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 116. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 117. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 118. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 119. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 120. UNITED STATES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 124. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 126. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 128. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 130. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 132. ASIA-PACIFIC ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 133. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 134. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 135. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 136. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 137. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 138. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 139. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 140. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 141. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 142. AUSTRALIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 143. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 144. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 145. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 146. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 147. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 148. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 149. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 150. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 151. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 152. CHINA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 153. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 154. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 155. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 156. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 157. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 158. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 159. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 160. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 161. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 162. INDIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 163. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 164. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 165. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 166. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 167. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 168. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 169. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 170. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 171. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 172. INDONESIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 173. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 174. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 175. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 176. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 177. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 178. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 179. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 180. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 181. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 182. JAPAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 183. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 184. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 185. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 186. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 187. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 188. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 189. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 190. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 191. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 192. MALAYSIA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 193. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 194. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 195. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 196. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 197. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 198. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 199. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 200. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 201. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 202. PHILIPPINES ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 203. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 204. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 205. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 206. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 207. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 208. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 209. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 210. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 211. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 212. SINGAPORE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 213. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 214. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 215. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 216. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 217. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 218. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 219. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 220. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 221. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 222. SOUTH KOREA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 223. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 224. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 225. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 226. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 227. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 228. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 229. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 230. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 231. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 232. TAIWAN ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 233. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 234. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 235. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 236. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 237. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 238. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 239. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 240. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 241. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 242. THAILAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 243. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 244. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 245. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 246. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 247. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 248. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 249. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 250. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 251. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 252. VIETNAM ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 265. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 266. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 267. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 268. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 269. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 270. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 271. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 272. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 273. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 274. DENMARK ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 275. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 276. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 277. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 278. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 279. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 280. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 281. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 282. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 283. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 284. EGYPT ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 285. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 286. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 287. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 288. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 289. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 290. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 291. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 292. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 293. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 294. FINLAND ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 295. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 296. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 297. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 298. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 299. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 300. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 301. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 302. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 303. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 304. FRANCE ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 305. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 306. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 307. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 308. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 309. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 310. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 311. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 312. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 313. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 314. GERMANY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 315. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 316. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 317. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 318. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 319. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 320. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 321. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 322. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 323. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 324. ISRAEL ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 325. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 326. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 327. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 328. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 329. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
TABLE 330. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
TABLE 331. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 332. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 333. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
TABLE 334. ITALY ANTIBODY DRUG CONJUGATE MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
TABLE 335. NETHERLANDS ANTIBODY DRUG CONJUGATE MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 336. NETHERLANDS ANTIBODY DRUG

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • ADC Therapeutics SA
  • Ambrx Biopharma Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Byondis B.V.
  • Celldex Therapeutics Inc.
  • Creative Biolabs, Inc.
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Heidelberg Pharma AG
  • ImmunoGen, Inc.
  • Innate Pharma SA
  • Innovent Biologics, Inc.
  • Lonza Group Ltd.
  • MacroGenics, Inc.
  • MediLink Therapeutics
  • Merck KGaA
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Oxford Biotherapeutics Limited
  • Pfizer, Inc.
  • Pheon Therapeutics Ltd.
  • Piramal Pharma Limited
  • Recipharm AB
  • Sanofi S.A.
  • Sorrento Therapeutics, Inc.
  • Tagworks Pharmaceuticals BV
  • Takeda Pharmaceutical Company Limited
  • Tubulis GmbH
  • Zymeworks Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.48 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.96 Billion
Compound Annual Growth Rate16.1%
Regions CoveredGlobal
No. of Companies Mentioned39

Related Topics

Related Reports

Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035 - Product Image

Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions (North America, Europe, and Asia-Pacific): Industry Trends and Global Forecasts, 2023-2035

  • Report
  • 716 Pages
  • Global
From
Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028 - Product Image

Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028

  • Report
  • 273 Pages
  • Global
From
Global Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Forecast 2024-2030 - Product Image

Global Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Forecast 2024-2030

  • Report
  • 193 Pages
  • Global
From
Antibody Drug Conjugates Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Distribution Channel, and Geography - Product Image

Antibody Drug Conjugates Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Distribution Channel, and Geography

  • Report
  • 178 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.